Scott Gottlieb

From Wikipedia, the free encyclopedia
Jump to: navigation, search
This article is about the American physician. For the drummer, see Scott Gottlieb (musician).

Scott Gottlieb is an American physician and conservative health policy analyst named in March 2017 as likely commissioner of the Food & Drug Administration (FDA) in President Donald Trump's administration.[1][2][3] He is a clinical assistant professor at New York University School of Medicine, a resident fellow at the conservative American Enterprise Institute, and an internist at Tisch Hospital.[4]

Early life and education[edit]

Prior to attending medical school, Gottlieb worked as a healthcare analyst at the investment bank Alex. Brown & Sons in Baltimore.

He completed a residency in internal medicine at the Mount Sinai Hospital in New York and is a graduate of the Icahn School of Medicine at Mount Sinai, where he received a medical degree, and of Wesleyan University, where he received a Bachelor's degree in economics.[5]

U.S. government work[edit]

Gottlieb has worked in multiple roles for the Federal government of the United States, including Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration (FDA), in which capacity he served from 2005 to 2007.[6] He helped initiate the early development of FDA's generic drug user fee program and the Agency's release of the Physician Labeling Rule. He also worked on development of the FDA's policies related to the tentative approval of fixed dose combination drugs for the treatment of HIV/AIDS under the PEPFAR program. He was appointed to the Senior Executive Service and granted a top secret security clearance during his appointment as FDA's Deputy Commissioner for Medical and Scientific Affairs. He was also as a member of the White House Biodefense Interagency Working Group, which was convened after the September 11, 2001 attacks to help draft a strategic plan for the development of U.S. biodefense countermeasures. While working for the FDA, Gottlieb had to recuse himself from working on planning for a possible bird flu epidemic due to his ties to pharmaceutical companies.[7] Before becoming the FDA's Deputy Commissioner, Gottlieb served as a senior advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development.[8]

In 2013, Gottlieb was appointed by the Senate Minority Leader Mitch McConnell to serve as a member of the Federal Health IT Policy Committee which advises the U.S. Department of Health and Human Services and is responsible for making recommendations on the meaningful use standards as part of the HITECH Act.[9] In 2016 members of President-elect Donald Trump's transition team said Trump was considering Gottlieb to head the FDA as its Commissioner.[10] Gottlieb worked as an advisor to, and then a member of the Trump Transition Team starting from the Summer of 2016. He was previously a Senior Advisor to the 2016 Presidential campaign of Wisconsin Governor Scott Walker.[11]

He has testified as an expert witness before committees of the United States House of Representatives and the United States Senate on issues related to FDA regulation,[12] healthcare reform,[13] and medical innovation.[14] Gottlieb is on the editorial board of the Food and Drug Law Institute's publication Food and Drug Policy Forum.[8][15]

Other roles[edit]

Gottlieb is a member of the Public Policy Committee to the Society of Hospital Medicine,[16] is an adviser to the National Coalition for Cancer Survivorship. He has been a venture partner at New Enterprise Associates since 2007,[15] and is an independent director at Tolero Pharmaceuticals,[17] and Daiichi Sankyo Inc,[18] and a member of GlaxoSmithKline's product investment board.[15] He is a senior healthcare advisor to BDO and also a partner at T.R. Winston, a Los Angeles-based merchant bank with a focus on healthcare.[19]

He has also worked as a senior policy advisor to the Administrator at the Centers for Medicare & Medicaid Services, where he worked on implementation of the Medicare Prescription Drug, Improvement, and Modernization Act and the Medicare Part D drug benefit, and helped advance the agency's coverage policies related to new medical technology.[20] Gottlieb was previously on the policy board to the Leukemia and Lymphoma Society[citation needed] and an advisor to Cancer Commons.[21]


Gottlieb is a former member of the editorial staff of the British Medical Journal (BMJ),[citation needed] and a member of the editorial board of a section of the Journal of the American Medical Association (JAMA).[citation needed]

He is a regular contributor to the editorial page of the Wall Street Journal and writes regularly for Forbes.[22] In his various writings, Gottlieb was a frequent and early critic of the Affordable Care Act. He wrote an editorial in the Wall Street Journal, the day of the health plan's launch, predicting the ensuing problems with the website. Gottlieb also appears regularly on CNBC[23] and Fox News.[24]


  1. ^ Neel, Joe (March 10, 2017). "Trump To Nominate Dr. Scott Gottlieb To Head Food And Drug Administration". NPR. Retrieved March 10, 2017. 
  2. ^ Thomas, Katie, "F.D.A. Official Under Bush Is Said to Be Trump’s Choice to Lead Agency", New York Times, March 10, 2017. Retrieved 2017-03-10.
  3. ^ Cunningham, Paige Winfield, "Trump expected to pick Scott Gottlieb to head FDA", Washington Examiner, March 10, 2017. Retrieved 2017-03-10.
  4. ^ Dalzell, Michael D. (2011). "A Conversation With Scott Gottlieb, MD: The impact of health care reform on access to biologics, health policy, and managed care.". Biotechnology Healthcare. 8 (3): 19–22. PMC 3278114Freely accessible. PMID 22479219. 
  5. ^ "Allyson Nemeroff, Scott Gottlieb". The New York Times. 13 June 2004. Retrieved 13 January 2017. 
  6. ^ "Deputy Commissioners". FDA. Retrieved 10 September 2016. 
  7. ^ Rosenberg, Martha (26 December 2007). "The Strange Career of Scott Gottlieb". Counterpunch. Retrieved 10 September 2016. 
  8. ^ a b "Dr. Scott Gottlieb". 1 March 2016. Retrieved 13 January 2017. 
  9. ^ "Health IT Policy Committee - FACA". Retrieved 13 January 2017. 
  10. ^ "Trump considering Dr. Scott Gottlieb to head FDA". 12 December 2016. Retrieved 13 January 2017 – via Reuters. 
  11. ^ Roll Call, Ahead of Obamacare Repeal Rollout, Walker Stocks Up On Advisers Familiar With Capitol Hill:
  12. ^ Gottlieb, Scott, "EpiPen Price Increases: How Regulatory Barriers Inhibit Pharmaceutical Competition", Statement before the Senate Committee on Health, Education Labor and Pensions: Subcommittee on Children and Families via AEI, October 7, 2016.
  13. ^ Gottlieb, Scott, MD, "Health Care Solutions: Increasing Patient Choice and Plan Innovation", Testimony before the United States House Committee on Energy and Commerce Subcommittee on Health via AEI, May 11, 2016.
  14. ^ Gottlieb, Scott, "Restoring the Trust for All Generations: Americans at or Near Retirement", Statement before the House Committee on the Budget via AEI, July 13, 2016.
  15. ^ a b c "Scott Gottlieb, MD - NEA - New Enterprise Associates". Retrieved 13 January 2017. 
  16. ^ Medicine, Society of Hospital. "Public Policy Committee - Society of Hospital Medicine". Retrieved 13 January 2017. 
  17. ^ "Board of Directors". Retrieved 13 January 2017. 
  18. ^ "Company DAIICHI SANKYO, INC.". Retrieved 13 January 2017. 
  19. ^ "Scott Gottlieb {first-person bio}", Retrieved 2017-03-10.
  20. ^ "Scott Gottlieb". American Enterprise Institute. Retrieved 10 September 2016. 
  21. ^ "Emeritus Advisory Board". Retrieved 2017-03-10.
  22. ^ Gottlieb, Scott. "Scott Gottlieb - Medical Innovation". Retrieved 13 January 2017. 
  23. ^ Gottlieb, Scott (29 August 2016). "Former FDA official explains why drug makers charge outrageous prices". Retrieved 13 January 2017. 
  24. ^ "Dr. Scott Gottlieb". 13 January 2017. Retrieved 13 January 2017. 

External links[edit]